The complement cascade is an ancient immune-surveillance system that not only provides protection from pathogen invasion but has also evolved to participate in physiological processes to maintain tissue homeostasis. The alternative pathway (AP) of complement activation is the evolutionarily oldest part of this innate immune cascade.
C3a receptor (C3aR). In the bigger split product, C3b, a reactive thioester becomes exposed upon convertase cleavage, enabling covalent attachment of this protein to nearby surfaces. Surface-attached C3b and its proteolytically processed products iC3b and C3dg remain surface-tethered via the thioester and act as opsonins that mark the C3b/iC3b/C3dg-decorated surfaces for removal by phagocytosis.
In the absence of adequate regulation, CP/LP-produced C3b molecules can self-amplify through a positive feedback loop of the AP; in a process that is commonly termed the "AP amplification loop," factor B (FB) binds to deposited C3b and becomes activated by factor D (FD) to form the AP C3 convertase complex (C3bBb), which cleaves additional C3 to C3b. Of note, AP C3 convertases may be further stabilized by the positive AP regulator properdin and thus promote complement activation. 4 Accumulation of C3b to high densities favors the proteolytic activation of C5, which marks the initiation of the TP. 5, 6 This activation is carried out by C5 convertases that process C5 into the potent anaphylatoxin C5a and the bigger split product C5b, which initiates the assembly of the membrane attack complex (MAC). The MAC can damage cells via insertion into their membranes, potentially leading to the formation of lytic pores. Thus, TP activation has the greatest inflammatory potential of the entire complement cascade.
Not merely a feedback loop for the amplification of CP/LPproduced C3b, the AP also constitutes a distinct initiation pathway.
The essence of the arbitrary nature of the AP and its activation lies in the structural organization of the central, thioester-containing molecule C3, which functions by analogy to early immune strategies observed in Cnidaria species such as sea anemones and corals. 7 Native F I G U R E 1 Sketch of the complement cascade. The complement cascade can be triggered by one of the three canonical activation pathways, the lectin (LP), the classical (CP), or the alternative pathway (AP). The central step in the three cascades is the activation of C3 into the anaphylatoxin C3a and the opsonin C3b through bimolecular C3 convertases (the proximal complement cascade). In the presence of complement regulators with cofactor activity, the plasma protease Factor I proteolytically inactivates C3b molecules into the late-stage opsonins iC3b and C3dg. If C3b inactivation does not proceed at sufficient speed, the AP-amplification loop provides a positive feedback mechanism. C3b molecules assemble more C3 convertases, followed by the production of more C3b molecules, thus amplifying the initial trigger manyfold. Newly produced C3b molecules can associate with the bimolecular C3 convertases of the proximal pathway to form the tri-molecular C5 convertases, marking the transition to the terminal (lytic) pathway. C5 convertases cleave, and thus activate, C5 into the anaphylatoxin C5a and C5b. Together with other complement components in serum, C5b builds membrane attack complexes. C5a is a potent anaphylatoxin and sends inflammatory signals to many different cells. Several other regulators efficiently control the cascade at different steps, including the proteins that cause the decay of the convertases. For simplicity, only cofactor activity is shown in this scheme ; however, as part of the so-called "tick-over" mechanism, spontaneous hydrolysis of the thioester in C3 occurs continuously in a small fraction of C3 molecules. This process produces C3(H 2 O) molecules that structurally and functionally resemble the proteolytic C3 activation product C3b. 9 In comparison to C3, C3(H 2 O) has undergone conformational rearrangements to expose its thioester, which, within a very short timeframe, can react with nucleophiles on nearby surfaces ( Fig. 2A) . Failure of individual C3(H 2 O) molecules to attach to surfaces leads to the presence of soluble C3(H 2 O) (or C3b) molecules that circulate in the fluid phase. 10, 11 It is generally thought that such conformation-driven auto-activation of C3 occurs spontaneous and arbitrarily, although contact-triggered C3 activation has been described for some surfaces.
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Foreign and host surfaces are considered similarly susceptible to constant probing by the AP through the deposition of C3(H 2 O) and/ or C3b. It is therefore essential to have powerful control mechanisms in place to discriminate between various threat levels and shape the complement response accordingly. In the presence of danger patterns and the absence of efficient regulation, complement marks affected particles with opsonins for phagocytic removal, assembles the cell-damaging MAC, and alarms the body through the release of the inflammatory and chemoattractant mediators C3a and C5a, which recruit phagocytes to the site of activation. 12 Induction of the same effector responses in host tissue would impose a serious threat to the host and disrupt body homeostasis, and therefore these responses need to be actively prevented.
| CONTROLLING COMPLEMENT: THE IMPORTANCE OF COMPLEMENT REGULATORS
Healthy host tissues counteract complement-mediated damage by relying on an arsenal of efficient regulators that are either membrane- 
| THE REGULATORS
Complement regulation needs to control all the major checkpoints of activation, amplification, and resulting effector functions and to cover both fluid-phase and surface activation. This need is reflected in the number and diversity of complement regulators, which encompass various circulating and membrane-bound 
| NON-CONVERTASE-DIRECTED REGULATION
Although the convertases act as the "motor" of complement activation, their actions are typically initiated by the sensing activities of the CP/LP, and they produce effectors that may potentially harm not only the intended target but also heathy cells. Therefore, both CP/ LP initiation and the TP effector arm need to be carefully controlled. 
| Regulation of initiation pathways

| Modulation of anaphylatoxin effector functions
Anaphylatoxins, and in particular C5a, are highly potent inflammatory mediators and chemoattractants whose spatiotemporal activity needs to be controlled. In addition to rapid systemic clearance of these effectors, carboxypeptidase has a direct regulatory role. Carboxypeptidases quickly tame anaphylatoxin activity by cleaving the C-terminal arginine residue of C3a and C5a, generating their desarginated ("desArg")
forms. Although the desArg forms were traditionally considered "inactive" or at least of markedly reduced potency, recent data indicate that C5a-desArg maintains significant levels of cell signaling activity. 28 Furthermore, C5a-desArg binds to a second C5a receptor (C5aR2, C5L2) with high affinity. Although the exact role of these events remains to be fully explored, it appears that desArg anaphylatoxins are not completely inactivated but may instead exhibit distinct biological functions when compared to the non-regulated forms.
| Regulation of the terminal pathway
The initiation of the TP is marked by the splitting of C5 into C5a and C5b. C5b associates with components C6 to C8 and multiple molecules of C9 to form C5b-9 complexes that efficiently insert into membranes. Whereas C5b-7 complexes can already enter and disturb membrane lipid bilayers, the insertion is inefficient and not very stable without the binding of C8 and C9. 29 The recruitment of C8 and C9
to C5b-7 complexes therefore marks a critical step in efficient MAC formation and a critical point-of-action for TP regulators.
Vitronectin (or S protein; not to be confused with protein S) is a secreted glycoprotein of approximately 75 kDa that is mainly produced in the liver and found in the circulation at a concentration of approximately 400 μg/mL. [30] [31] [32] In addition, vitronectin is detected in many tissues. Recent data suggest that this glycoprotein, which contains an RGD integrin motif, acts as an adhesive protein in the extracellular space and interstitium to facilitate mammalian tissue repair and remodeling, particularly after trauma [reviewed in (33) ]. In terms of complement regulation, vitronectin binds to nascent C5b-7, C5b-8, and C5b-9 complexes, blocks their incorporation into cell membranes, and prevents the polymerization of C9. 32 Vitronectin-bound complexes of the TP components C5b to C9 are commonly referred to as "SC5b-9." Finally, vitronectin is also thought to help solubilize SC5b-9 complexes by binding to hydrophobic patches in C5b-9 and preventing protein aggregation.
The inhibitory mechanism of the amphiphilic protein clusterin (apolipoprotein J; SP-40, 40) resembles that of vitronectin. Clusterin scavenges nascent C5b-7, C5b-C8, and C5b-9 complexes in the fluid phase before they can come into contact with a lipid bilayer, and thereby it inhibits the membranolytic insertion of soluble TP complexes. 34 Clusterin can also become incorporated into SC5b-9 complexes, suggesting some orthogonality in the regulatory mechanisms of these two fluid-phase TP inhibitors. Clusterin is a approximately 70-80 kDa glycoprotein, consisting of two disulfide-linked polypeptide chains (α and β), that is secreted into plasma. Aside from this circulating form of clusterin, which has cytoprotective effects, other less abundant, non-secreted forms of clusterin are believed to have chaperone-like functions. 35 Specific isoforms of and sequence variations in clusterin have been linked to the development of Alzheimer's disease, 36 and modulation of apoptosis has been associated with certain cancers [reviewed in (37) ].
On most host-cell surfaces, the major regulator of TP activity is the glycosylphosphatidylinositol (GPI)-anchored protein CD59 (protectin). Human CD59 is a 20-kDa glycosylated protein that shows exceptionally broad distribution across many human cells and tissues.
As a result of enzymatic cleavage of the GPI by phospholipase C, a minor fraction of the polypeptide can also be found in soluble form (e.g. in blood plasma or urine). CD59 inhibits the final sequence of MAC assembly on cell membranes by binding to C8 and C9 within C5b-8 or C5b-9 complexes and inhibiting further recruitment and polymerization of C9 into a cytolytic pore. CD59 deficiency can occur in isolation as the result of a homozygous mutation in the encoding gene, leading to a global absence of functional CD59 from all cell surfaces. 38, 39 In PNH patients, somatic mutations in hematopoietic stem cells affect enzymes that are essential for producing GPI anchors (most commonly observed in the PIG A gene). Mutated enzymes lead to a relative or absolute absence of GPI-anchored proteins from the progeny of the affected stem cells, including the complement regulators CD59 and CD55 (DAF; see below). 40 
| CONVERTASE-DIRECTED REGULATORS
A key feature of the complement cascade is that it allows for rapid ac- FI, a 63-kDa glycoprotein built from two polypeptide chains that is primarily synthesized by the liver, is a highly specific serine protease requiring the presence of a suitable cofactor that mediates substrate binding. It is thought to circulate in a proteolytically inactive form that is maintained by the non-catalytic heavy chain, which allosterically modulates the enzymatic activity of the serine protease domain.
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Only in a ternary complex with a cofactor and the substrate (C3b or and its alternative splice product Factor H-like 1 (FHL-1) ( Table 2 and Fig. 3 ). Down-regulation of complement activation has to take place selectively on healthy self-surfaces and in the fluid phase (to prevent consumption), but complement activity must be allowed to proceed against microorganisms and other unwanted particles. Given their distinct profiles concerning localization, CA/DAA activity, and target specificity (Table 2) , the RCA proteins act in concert to provide the required selectivity.
| Membrane-bound convertase regulators
Since membrane-bound regulators are embedded in the cell membrane, their regulatory functions are restricted to the host surfaces they protect. Of the three RCA members that are tethered to the plasma membrane, CR1 and MCP are embedded via transmembrane domains, whereas DAF is fixed to the outside membrane leaflet via a GPI anchor.
CR1 is an integral membrane glycoprotein composed of an Nterminal ectodomain, a transmembrane region, and a C-terminal cytoplasmic tail (Fig. 4A ). A size polymorphism in the ectodomain, which has arisen through duplication or deletion of highly homologous repeating units termed long homologous repeats (LHR), results in four known polypeptide sizes 57 containing three to six LHR. The most abundantly observed CR1 size variant is built from 30 CCP domains, which are organized in four LHR (A-D) of seven CCPs, followed by two additional CCP domains at the C-terminus. In LHR A-C, the regulatory functions are located in the three most amino-terminal CCPs, whereas LHR D does not exhibit regulatory activity. 58, 59 Regulatory site 1 encompasses CCPs1-3 in LHR A and harbors DAA for both the CP/LP and AP. 60 There are two copies of regulatory site 2 within LHR B (CCPs8-10) and LHR C (CCPs15-17)
that are virtually identical in sequence and function; these sites bind C3b and C4b more efficiently than does site 1, and they have CA for FImediated cleavage of these opsonins. 61 The three functional sites are thought to cooperate when CR1 binds to surface patches bearing clusters of C3b and C4b molecules. 61, 62 In addition to efficiently controlling complement activation, the transport of C3b-and C4b-opsonized immune complexes to the spleen and liver is another major function of CR1 on red blood cells (termed "immune adherence"). 63 The number polymorphism of CR1 has pathological implica- 
| Soluble convertase regulators
The RCA family of proteins includes three soluble regulators, C4BP, potential mechanism for targeting apoptotic cells. 79, 80 It is noteworthy that the majority of circulating C4BP exists as a complex with protein S as the result of a strong interaction mediated by the C4BP β-chain.
| FH and FHL-1
FH, a 155-kDa glycoprotein, is the major fluid-phase regulator of the AP and is solely composed of 20 CCP domains (Fig. 4B) . The AP-mediated kidney condition C3G is characterized by abnormal complement activity resulting from sequence variations in, or autoantibodies against, convertase-directed regulators or complement effectors. 
| NOVEL INSIGHTS IN FH AND FHL-1 BIOLOGY
One of the fascinating features of FH is that it can act as both a fluid-phase regulator, inhibiting consumption of AP components in circulation, and as a surface regulator by binding to host cells. This versatility is largely determined by its structural organization, which is solely built from CCP domains that are organized into multiple functional units. The four N-terminal CCP domains in FH contain all the regulatory functionality of FH, while CCP7 and CCP20 contain the host-surface recognition patches that specifically recognize negatively charged sialic acid and GAG moieties on host surfaces (Fig. 4B) . 93 The regulatory functions of FH encompass causing the decay of AP convertases as well as enabling the FI-mediated degradation of C3b to iC3b. Both tasks necessitate the binding of FH to its target, C3b, for which it employs two C3b-binding regions located in the four domains nearest the N-terminus (FH1-4) and the two domains nearest the C-terminus (FH19-20 This is remarkable, since full-length FH strongly binds C3b but fails to efficiently recognize either iC3b or C3dg. Therefore, within the FH molecule, the C-terminal domains must be hidden in a compact, rather than linear, overall conformation of the 20 CCP domains.
Early biophysical data were interpreted to suggest that the 20 FH domains are arranged linearly, resulting in a flexible, extended structure, and therefore the functional activities of single domains or domain stretches would simply "add up". 81 This view was amended by further biophysical studies, which indicated that FH assumes a foldedback, yet still flexible conformation. 97 It was suggested that the affinity and regulatory potency of FH is low for a single C3b but enhanced for C3b clusters, a situation that was explained by the supposedly flexible FH structure that allows the various C3b binding sites within FH to connect between adjacent, surface-attached C3b molecules (Fig. 5A ).
Polyanionic self-markers were proposed to induce multimerization of flexible FH molecules and further increase the avidity for C3b clusters on host surfaces. 
| INSIGHTS INTO FHL-1 FUNCTION
| AN UPDATED STRUCTURAL MODEL OF FH
In terms of functional sites, the most obvious difference between FH and FHL-1 is that FHL-1 lacks the C-terminal domains, CCPs19-20. These findings concerning FH's structure can be reconciled by a structural model in which a compact center arranges the N-terminal half of FH so as to shield the C-terminal domains in a partially cryptic conformation (Fig. 5B) . The occluded C-terminus may be released when the N-terminus engages C3b. It is anticipated that such conformational rearrangement into an "open" FH conformation upon C3b binding is facilitated by the simultaneous binding to polyanionic markers on host surfaces. This structural model also provides an explanation for the finding that recombinant FH CCPs19-20 in isolation can efficiently bind to TED in the C3b degradation products iC3b and C3dg, 127 but the same domains within FH cannot. 122, 125, 128 Only a compact and simultaneously rigid FH conformation can actively shield the C-terminal engagement of TED by occluding the TED binding site on CCPs19-20. Evidence for a compact FH conformation has already been described earlier. 118 The updated model also predicts the domain arrangement in FH to be rigid, since a cryptic C-terminus, and the functional data supporting its relevance, could not be brought into 
| THE UPDATED STRUCTURAL ROLE OF FH IN THE LIGHT OF EVOLUTION
Although some functional aspects of FH regulation still need to be revisited in the light of the new molecular insights, one can already speculate about why evolution would favor a mode in which a shielded C-terminus restricts the binding of FH to the C3b degradation fragments iC3b and C3dg:
1. Improved selectivity for danger is one potential explanation. 
| INTERPLAY BETWEEN PATHOGENS AND COMPLEMENT REGULATORS
The principle mode of action of the ancient innate immune defense directed to discriminate between host and invader largely relies on a "missing self-protection," i.e. the absence of regulators and self-makers on foreign cells that protects them from host defense systems, and in particular, from complement. However, the evolutionary pressure on invading microbes paved the way for the development of several strategies that allow to subvert complement attack to successfully invade the human host [reviewed in (13) 
| THE TRANSLATIONAL APPROACH: ENGINEERING OF NATURAL COMPLEMENT REGULATORS
As illustrated above, inappropriate regulation of complement activity is increasingly recognized as a causal or exacerbating factor in a number of human diseases [reviewed in (147) 
| ENGINEERED FH-BASED REGULATORS
As the major AP-specific regulator that harbors both DAA and CA Notably, the different linker lengths introduced between the two C3b binding sites of the engineered miniFH versions influenced the ability to protect PNH cells. The optimized peptide linker in miniFH showed the highest activity in PNH cell protection, illustrating that an optimal spatial orientation between functional domain segments is important for potentiating inhibitory activity on host cells.
To a certain degree, the regulatory mechanism of miniFH is com- Amyndas.
In conclusion, the design and characterization of engineered FHbased regulators has already resulted in interesting molecules with therapeutic potential that are undergoing further evaluation in clinically relevant disease models. Comparing various engineered constructs of the natural regulators FH and FHL-1 has also advanced our insights into the general requirements of convertase-driven complement regulation and suggests that the turnover rate of the regulators plays a role in determining anti-complement activity.
| FUTURE ASPECTS OF CONVERTASE-DIRECTED REGULATION
Convertase-directed regulators fulfill the vital task of tightly controlling complement activation and amplification processes early on in the cascade and keeping the critical balance between activation and regulation to maintain tissue homeostasis. Ideally, the diverse regulators work in concert to (selectively) allow a necessary minimum of complement activation for the cascade to perform its continuous immune-surveillance functions. The collaboration between regulators has to be dynamically adapted to cope with different threat situations.
Aside from specific activation events, which are mainly controlled through the pattern recognition complexes of the CP/LP, it is the mix of available complement regulators that determines the functional consequences of complement activation. Pathogens devoid of regulators ideally face a full-scale response, including effector generation that leads to direct killing and/or phagocytic removal, whereas a milder response restricted to opsonization should be induced by dying host cells. Efficient removal of apoptotic cells largely depends on the FI-and regulator-mediated conversion of C3b to iC3b and subsequent uptake by macrophages via CR3 and CR4. 164 In contrast to phagocytosis of iC3b-opsonized microbes by CR3, which creates an overall inflammatory milieu, 165 the complement-dependent uptake of apoptotic bodies via the iC3b-CR3/CR4 axis promotes an antiinflammatory signature with TGFβ release. 164, [166] [167] [168] Conversion of C3b to iC3b on apoptotic cells appears to depend on the recruitment of FH, which binds to several surface molecules on apoptotic bodies. 169 Thus, the preformed regulators of defense not only negatively regulate the complement cascade to influence whether proximal or terminal signals are liberated but also produce the CR3-ligands iC3b
and C3dg to direct efficient and anti-inflammatory uptake of turnover products to aid tissue homeostasis.
There is increasing evidence that iC3b molecules on self-particles promote an anti-inflammatory, potentially tolerogenic milieu through the recognition of iC3b by CR3. 170, 171 Given that C3dg has recently also been considered a ligand of CR3, the same notion probably holds true for C3dg-tagged self-cells. 158, 172 It will be very exciting to see how future studies will address this emerging theory of iC3b/C3dg-mediated fostering of anti-inflammatory signals, especially in the context of complement-mediated diseases such as AMD. 173, 174 Convertasedirected complement regulators are expected to play a major part in this process, since they are responsible for generating the late-stage opsonins iC3b and C3dg from the C3 activation product C3b.
The past few years have generated a wealth of new and fascinating insights into the molecular mechanisms of complement regulators, their involvement in disease processes, and their potential for therapeutic use. In view of emerging concepts such as competitive de-regulation, context-specific accessibility of binding/targeting sites, and regulator-mediated modulation of inflammatory responses, the coming decades in the research into preformed complement regulators promise to be equally exciting.
